ADTX - aditxt.com Debt to Book Capitalization Ratio

Graphic logo of Aditxt, Inc. (ADTX)

The dynamics of the debt-to-book capitalization ratio for Aditxt (ADTX) help track the market value of debts, where the value 0.00 indicates the current magnitude. Demand for immunodiagnostics remains stable, although a recession could slow the adoption of technologies. However, the business is burdened by critical cash burn and share dilution, while aggressive asset acquisitions create acute cash pressure and a liquidity deficit.

ADTX (Aditxt, Inc.) Debt to Book Value history from 07/04/2022 to 07/11/2026
Core merchandise of aditxt.com

Aditxt operates high-tech diagnostic laboratories in the US, which require significant capital expenditures in infrastructure. The total liabilities-to-equity ratio measures the degree of financial leverage and the overall solvency of the issuer. By analyzing the level of debt concentration within the balance sheet capitalization, an investor assesses the default risk relative to the value of net assets. This metric reflects the financing efficiency of process automation and equipment provisioning. A low ratio confirms the fundamental stability and autonomy of the business.

Who Aditxt competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Immunome Corp - Debts to Book Capitalization|GOSS - Debts to Book Capitalization|Debts to Book Capitalization KalVista Pharmaceuticals|septerna.com (SEPN) - Debt to Book Value Ratio|PVLA: Debts to Book Capitalization|Debts to Net Assets Savara Inc (SVRA)|Debt to Book Value Rigel Pharmaceuticals Inc|Debt to Book Capital AnaptysBio Inc. ANAB|ATXS - Debt to Book Value|ENGN - Debt to Book Value Ratio|Debt to Book Value RAPT Therapeutics, Inc. RAPT|JBIO - Debt to Book Capital|ACRS: Debts to Book Capitalization|Kyverna Therapeutics, Inc (KYTX) - Debts to Book Capitalization|Debts to Book Capitalization Tiziana Life Sciences (TLSA)|Debt to Book Value Ratio cabalettabio.com (CABA)|Debt to Book Value Ventyx Biosciences, Inc.|Debt to Book Capital Theratechnologies, Inc. THTX|AVTX - Debt to Book Value|Eledon Pharmaceuticals, Inc - Debt to Book Value Ratio|Debt to Book Capitalization Ratio Agenus|CLYM - Debts to Book Capitalization Ratio|Debts to Book Capitalization Zura Bio Limited ZURA|aTyr Pharma Inc (ATYR) - Debt to Net Assets Ratio|ADAG (Adagene Inc) - Debts to Book Capitalization|Debts to Book Capitalization IMA|Shattuck Labs, Inc. (STTK) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio EQ (equilliumbio.com)|Connect Biopharma Holdings Limited - Debt to Book Capitalization Ratio|Debt to Book Value Immunic Therapeutics IMUX|Atara Biotherapeutics Inc - Debts to Book Capitalization|InflaRx N.V. (IFRX) - Debts to Book Capitalization|Debt to Book Value X4 Pharmaceuticals XFOR|Adicet Bio, Inc. (ACET) - Debt to Net Assets Ratio|CELU: Debts to Book Capitalization|Debts to Net Assets INMB|Debt to Book Capitalization Ratio BRNS (Barinthus Bio)|Debt to Book Value KZR (Kezar Life Sciences Inc)|SAB Biotherapeutics - Debt to Book Capitalization Ratio|AKTX - Debt to Book Value|Enlivex Therapeutics, Ltd. - Debt to Book Value|QTTB: Debts to Book Capitalization|Debt to Book Capitalization Ratio GeoVax Labs Inc|Edesa Biotech Corp (EDSA) - Debt to Book Value Ratio|Debts to Book Capitalization IBIO (iBio, Inc.)|Debts to Book Value Carisma Tx|Debts to Book Capitalization XTLB|Debts to Book Capitalization boltbio.com (BOLT)|HCWB - Debts to Book Capitalization|Debt to Book Value Ratio Aptevo Therapeutics, Inc. APVO|Debts to Book Capitalization AIM (AIM ImmunoTech)|gribio.com (GRI) - Debts to Net Assets|XRTX - Debt to Book Value|Debt to Book Capital Vyome Holdings Inc.|Debt to Book Value Revelation Bio (REVB)|Debt to Book Value Ratio Indaptus Corp (INDP)|Debt to Book Value Scinai Immunotherapeutics|Debt to Book Capital calcimedica.com (CALI)|Debts to Book Capitalization AFMD (Affimed N.V.)|Debts to Book Capitalization Allakos Inc ALLK|HOOKIPA (HOOK) - Debts to Book Capitalization|IGM Biosciences, Inc. (IGMS) - Debt to Book Value Ratio|ITOS - Debt to Book Value|Debt to Book Capital oceanbiomedical.com|Debt to Book Value TC BioPharm (TCBP)|Debt to Book Value Ratio THRD